

# Cadila Healthcare Limited


Registered Office : Zydus Tower, Satellite Cross Roads, Ahmedabad - 380015.  
Tel. No. : (+91-79) 2686 8100 Fax No. : (+91-79) 2686 2365/66 Website : www.zyduscadila.com  
Unaudited (Provisional) Financial Results for the Quarter ended September 30, 2011.



CONSOLIDATED		Rupees in Lacs [ except for share data ]			
		3 Months Period ended on September 30, 2011 [Unaudited]	6 Months Period ended on September 30, 2011 [Unaudited]	Corresponding 6 Months Period ended on September 30, 2010 [Unaudited]	Previous accounting Year ended on March 31, 2011 [Audited]
Sr. No.	Particulars	COMPANY			
		3 Months Period ended on September 30, 2011 [Unaudited]	6 Months Period ended on September 30, 2011 [Unaudited]	Corresponding 6 Months Period ended on September 30, 2010 [Unaudited]	Previous accounting Year ended on March 31, 2011 [Audited]
1	Sales & Income from operations :				
A	Gross Sales	112,135	242,777	218,954	452,111
B	Less : Excise Duty	1,923	3,462	2,813	5,644
C	Net Sales	110,632	239,315	216,141	446,467
D	Other Income from Operations	1,676	8,894	8,906	16,552
E	Total sales and other income from operations	112,640	248,209	225,047	463,019
2	Expenditure :				
A	Increase (-) / Decrease (+) in stock in trade & works in progress	(5,660)	(11,967)	(3,651)	599
B	Consumption of materials	33,037	59,518	50,690	100,711
C	Purchase of finished goods	11,678	27,707	20,969	46,228
D	Employees cost	18,029	34,176	26,916	50,892
E	Depreciation, Amortisation & Impairment	3,754	7,226	6,183	12,692
F	Other Expenditure	42,849	84,829	75,301	151,070
G	Total Expenditure	102,697	201,489	177,010	373,092
3	Profit from Operations before Other Income, Interest & Exceptional Items [ 1 - 2 ]	19,953	46,720	48,037	89,927
4	Other Income	1,104	1,735	672	1,311
5	Profit before Interest & Exceptional Items [ 3 + 4 ]	21,057	48,455	48,709	91,238
6	Interest & Finance charges	7,686	8,801	4,759	6,992
7	Profit after Interest but before Exceptional Items [ 5 - 6 ]	13,371	39,654	43,950	84,246
8	Exceptional Items (+) Income / (-) Expense	0	0	0	0
9	Profit (+) / Loss (-) from Ordinary Activities before tax [ 7 + 8 ]	13,371	39,654	43,950	84,246
10	Tax expense	2,351	5,205	5,916	10,636
11	Net Profit (+) / Loss (-) from Ordinary Activities after tax [ 9 - 10 ]	11,020	34,449	38,034	73,610
12	Extraordinary items (net of tax expense)	0	0	0	0
13	Net Profit (+) / Loss (-) for the period [ 11 - 12 ]	11,020	34,449	38,034	73,610
14	Adjustments on consolidation (+) Income / (-) Expense	(752)	(1,193)	(1,032)	(2,510)
15	Net Profit (+) / Loss (-) for the period [ 13 + 14 ]	10,268	33,256	37,002	71,100
16	Paid-up equity share capital : Face Value Rs. 5/-	10,237	10,237	10,237	10,237
17	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	0	0	0	206,911
18	Earnings Per Share [ EPS ] [ For the period - not Annualised ]:				
A	Basic and Diluted EPS before Extraordinary items [ Rs. ]	5.01	16.24	18.07	34.23
B	Basic and Diluted EPS after Extraordinary Items [ Rs. ]	5.01	16.24	18.07	34.23
19	Public shareholding :				
	- Number of shares	51,610,474	51,610,474	51,610,474	51,610,474
	- Percentage of Shareholding	25.21%	25.21%	25.21%	25.21%
20	Promoters and Promoter group Shareholding :				
A	Pledged / Encumbered :				
	- Number of Shares	Nil	Nil	Nil	Nil
	- Percentage of shares [ as a % of the total shareholding of promoters and promoter group ]	N.A.	N.A.	N.A.	N.A.
B	Non-encumbered :				
	- Number of Shares	153,136,046	153,136,046	153,136,046	153,136,046
	- Percentage of shares [ as a % of the total shareholding of promoters and promoter group ]	100%	100%	100%	100%
	- Percentage of shares [ as a % of the total share capital of the company ]	74.79%	74.79%	74.79%	74.79%

- Notes :
- (1) The above results for the quarter / half year ended on September 30, 2011 were reviewed by the Audit Committee on November 3, 2011 and then approved by the Board of Directors at their meeting held on November 10, 2011.
  - (2) The change in Investments during the quarter are as under :  
Zydus 359 Pharma Private Limited ( Additional Investment ) - Rs. 205 Lacs  
ZEST Aviator Private Limited - Rs. 230 Lacs
  - (3) During the quarter Zydus Animal Health Limited, a wholly owned subsidiary Company, has acquired 100% stake in Finest Procuring Solutions Limited to acquire the animal health business of Bionza Pharma GmbH, Germany.
  - (4) The above financial results include an unrealised loss on account of foreign exchange fluctuations of Rs. 7096 Lacs ( Rs. 8322 Lacs on consolidated basis ) for the quarter ( Rs. 5973 Lacs ( Rs. 6563 Lacs on consolidated basis ) for the half year ) ended September 30, 2011.
  - (5) The status of investor complaints :  
Pending at the beginning of the quarter - Nil, received and disposed off during the quarter - 19, pending at the end of the quarter - Nil.  
( Rs. 5973 Lacs ( Rs. 6563 Lacs on consolidated basis ) for the half year ) ended September 30, 2011.
  - (6) The Company has one segment of activity viz., "Pharmaceuticals".

CONSOLIDATED				COMPANY			
Rupees in Lacs				Rupees in Lacs			
6 Months Period ended on September 30, 2011 (Unaudited)	6 Months Period ended on September 30, 2010 (Unaudited)	Previous accounting Year ended on March 31, 2011 (Audited)	St. No.	6 Months Period ended on September 30, 2011 (Unaudited)	6 Months Period ended on September 30, 2010 (Unaudited)	Previous accounting Year ended on March 31, 2011 (Audited)	Particulars
10,237	10,237	10,237	1	10,237	10,237	10,237	Shareholders' Funds :
238,349	189,302	206,911	A	237,144	190,011	199,754	Costs
198,571	109,023	109,734	B	109,448	60,257	56,400	Reserves and Surplus
7,963	5,060	6,692	2	0	0	0	Loan Funds
11,681	11,657	11,656	3	0	0	0	Miscellaneous Interest
466,251	335,079	344,840	4	12,334	11,694	11,930	Deferred Tax Liability / (Asset)
261,855	204,736	226,364	5	369,163	222,309	277,321	Total Sources of Funds
17,020	2,069	2,069	6	138,366	114,391	127,032	Fixed Assets
96,902	83,744	81,185	7	83,858	68,371	69,878	Investments
70,753	61,564	76,524	B	48,725	45,058	46,452	Current Assets, Loans and Advances :
50,566	26,316	29,520	A	46,405	49,301	47,598	Inventories
52,881	36,744	41,063	B	35,342	3,054	4,238	Sundry Debtors
89,534	83,084	89,554	C	65,771	44,498	50,698	Cash and Bank Balances
7,245	6,726	22,331	D	46,242	47,736	50,355	Loans and Advances
1,553	(314)	0	A	4,002	4,244	19,046	Less : Current Liabilities and Provisions
466,751	325,079	344,840	B	1,040	(324)	0	Liabilities
			10	369,163	272,969	277,321	Provisions
			11				Foreign Currency Monetary Items Translation Difference Account
							Total Application of Funds

For Cadila Healthcare Limited,  
  
 Pankaj R. Patel  
 Chairman & Managing Director